ABSTRACT
Background The 10-year Atherosclerotic Cardiovascular Disease (ASCVD) risk score is the standard approach to predict risk of incident cardiovascular events and recently, addition of CAD polygenic scores (PGSCAD) have been evaluated. Although age and sex strongly predict the risk of CAD, their interaction with genetic risk prediction has not been systematically examined.
Objectives This study performed an in-depth evaluation of age and sex effects in genetic CAD risk prediction.
Methods The population-based Norwegian HUNT2 cohort of 51,036 individuals was used as the primary dataset. Findings were replicated in the UK Biobank (372,410 individuals). Models for 10-year CAD risk were fitted using Cox proportional hazards and Harrell’s concordance index, sensitivity, and specificity were compared.
Results Inclusion of age and sex interactions of PGSCAD to the prediction models increased C-index and sensitivity likely countering the observed survival bias in the baseline. The sensitivity for females was lower than males in all models including genetic information. The two-step approach identified a total of 82.6% of incident CAD cases (74.1% by ASCVD risk score and an additional 8.5% by the PGSCAD interaction model).
Conclusion These findings highlight the importance and complexity of genetic risk in predicting CAD. There is a need for modeling age and sex-interactions terms with polygenic scores to optimize detection of individuals at high-risk, those who warrant preventive interventions. Sex-specific studies are needed to understand and estimate CAD risk with genetic information.
CONDENSED ABSTRACT This study used two large population-based longitudinal datasets to evaluate genetic prediction of CAD including age and sex interactions. The model fit and sensitivity of the prediction models increased when including age and sex interaction of PGSCAD to the prediction models likely countering the observed survival bias in the baseline. The sensitivity for females was lower than for males in all models including genetic information. Our results highlight the importance and complexity of genetic risk and suggest including age and sex interactions with polygenic scores to identify more high-risk individuals for preventive interventions.
Competing Interest Statement
CJWs spouse works for Regeneron Pharmaceuticals. NRS serves on advisory committees for Cordis and Philips and has received honoraria for speaking from Zoll and Cordis. All other authors have nothing to disclose.
Funding Statement
Funding: Cristen J. Willer is supported by the National Institutes of Health (R01-HL127564, R35-HL135824, and R01-HL142023). Ida Surakka is supported by a Precision Health Scholars Award from the University of Michigan Medical School. Nadia R. Sutton is supported by the National Institutes of Health (1K76AG064426-01A1). Michael Inouye is supported by the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014) [The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care]. Acknowledgements: The authors thank the HUNT and UK Biobank participants for their contributions to research. HUNT-MI study, which comprises the genetic investigations of the HUNT Study, is a collaboration between investigators from the HUNT study and University of Michigan Medical School and the University of Michigan School of Public Health. The K.G. Jebsen Center for Genetic Epidemiology is financed by Stiftelsen Kristian Gerhard Jebsen; Faculty of Medicine and Health Sciences, NTNU, Norwegian University of Science and Technology (NTNU) and Central Norway Regional Health Authority. This research has been conducted using the UK Biobank Resource under Application Number 7439. This work was supported by core funding from the: British Heart Foundation (RG/13/13/30194; RG/18/13/33946), Cambridge BHF Centre of Research Excellence (RE/13/6/30180) and NIHR Cambridge Biomedical Research Centre (BRC-1215-20014) [The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care]. This work was also supported by Health Data Research UK, which is funded by the UK Medical Research Council, Engineering and Physical Sciences Research Council, Economic and Social Research Council, Department of Health and Social Care (England), Chief Scientist Office of the Scottish Government Health and Social Care Directorates, Health and Social Care Research and Development Division (Welsh Government), Public Health Agency (Northern Ireland), British Heart Foundation and Wellcome. The authors thank Kuan-Han Wu for his important graphical contributions.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Participation in the HUNT Study is based on informed consent and the study has been approved by the Data Inspectorate and the Regional Ethics Committee for Medical Research in Norway (REK: 2014/144)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* These authors jointly supervised this work and share co-senior authorship/correspondence
Funding: Cristen J. Willer is supported by the National Institutes of Health (R01-HL127564, R35-HL135824, and R01-HL142023). Ida Surakka is supported by a Precision Health Scholars Award from the University of Michigan Medical School. Nadia R. Sutton is supported by the National Institutes of Health (1K76AG064426-01A1). Michael Inouye is supported by the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014) [The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care].
Disclosures: CJW’s spouse works for Regeneron Pharmaceuticals. NRS serves on advisory committees for Cordis and Philips and has received honoraria for speaking from Zoll and Cordis. All other authors have nothing to disclose.
Data Availability
UK Biobank is freely available for research purposes (https://www.ukbiobank.ac.uk). HUNT2 summary level data is available upon reasonable request.
Abbreviations
- (ASCVD)
- Atherosclerotic cardiovascular disease
- (Harrell’s C-index, referred to as C-index throughout the study)
- Concordance index
- (CAD)
- Coronary artery disease
- (HRs)
- Hazard ratios
- (PCE)
- Pooled Cohort Equation
- (PGS)
- polygenic score
- (HUNT)
- Trøndelag Health Study
- (UK Biobank)
- United Kingdom Biobank
